書籍詳細

招待講演

P.9 掲載の参考文献

• 1) Teng CT:Factors regulating lactoferrin gene expression. Biochem Cell Biol 84:263-267, 2006.
  pubmed

• 2) Siebert PD. Huang BC:Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumorderived cell lines. Proc Natl Acad Sci US 94:2198-2203, 1997.

• 3) Liu D, Wang X, Zhang Z, Teng CT:An intronic alternative promoter of the human lactoferrin gene is activated by Ets. Biochem Biophys Res Comm 301:472-479. 2003.
  pubmed

• 4) Teng CT. Gladwell W:Single nucleotidc polymorphisms (SNPs) in human lactoferrin gene. Biochem Cell Biol 84:381-384, 2006.

• 5) Spik G, Coddeville B, Montreuil J:Comparative study of the primary structures of sero-, lacto- and ovotransferrin glycans from different species. Biochimie 70:1459-1469, 1988.
  pubmed

• 6) Montreuil J, Tonnelat J, Mullet S:Preparation and properties of lactosiderophilin (lactotransferrin) of human milk. Biochim Biophys Acta 45:413-421. 1960.
  pubmed

• 7) Baker EN, Baker HM:A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 91:3-10, 2009.
  pubmed

• 8) Legrand D. Pierce A, Elass E, Carpentier M, Mariller C et al.:Lactoferrin structure and functions. Adv Exp Med Biol 606:163-194, 2008.
  pubmed

• 9) Mazurier J, Spik G:Comparative study of the iron-binding properties of human transferrins. I. Complete and sequential iron saturation and desaturation of the lactotransferrin. Biochim Biophys Acta 629:399-408, 1980.
  pubmed

• 10) Breton M. Mariller C, Benaissa M, Caillaux K, Browaeys E et al.:Expression of delta-lactoferrin induces cell cycle arrest. Biometals 17:325-329,
  pubmed

• 11) Mariller C, Benaissa M, Hardiville S, Breton M., Pradelle G et al.:Human delta-lactoferrin is a transcription factor that enhances Skp1 (S-phase kinase-associated) gene expression. FEBS J 274:2038-2053, 2007.
  pubmed

• 12) Velliyagounder K, Kaplan JB, Furgang D, Legarda D, Diamond G et al. :One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis. Infect Immun 71: 6141-6147, 2003.
  pubmed

• 13) Wu YM, Juo SH, Ho YP, Ho KY, Yang YH et al. : Association between lactoferrin gene polymorphisms and aggressive periodontitis among Taiwanese patients. J Periodontal Res, 2008 (Epub ahead of print)

• 14) O'Halioran F, Bahar B, Buckley F, O'Sullivan O, Sweeney T et al. :Characterisation of single nucleotide polymorphisms identified in the bovine lactoferrin gene sequences across a range of dairy cow breeds. Biochimie 91:68-75, 2009.

• 15) Hardiville S, Hoedt E, Mariller C, Benaissa M, Pierce A et al. :The O-GlcNAc/phosphate interplay regulates delta-lactoferrin stability and transcription activity. J Cell Biol, 2009 (submitted).

• 16) Hart GW, Kreppel LK, Comer FL, Arnold CS, Snow DM et al. :O-GlcNAcylation of key nuclear and cytoskeletal proteins:reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology 6:711-716, 1996.

• 17) Mariller C, Hardiville S, Hoedt E, Benaissa M, Mazurier J et al. :Proteomic approach to the identification of novel delta-lactoferrin target genes:Characterization of DcpS, an RNA scavenger decapping enzyme. Biochimie 91:109-122, 2009.

• 18) Valenti P, Antonini G:Lactoferrin:an important host defence against microbial and viral attack. Cell Mol Life Sci 62:2576-2587, 2005.
  pubmed

• 19) Jenssen H, Hancock RE:Antimicrobial propcrtics of lactoferrin. Biochimie 91:19-29, 2009.

• 20) Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin:a modulator of immune and infiammatory responses. Cell Mol Life Sci 62:2549-2559, 2005.

• 21) Ward PP, Paz E, Conneely OM:Multifunctional roles of lactoferrin l a critical overview. Cell Mol Life Sci 62:2540-2548, 2005.

• 22) Konishi M, Iwasa M, Yamauchi K, Sugimoto R, Fujita N et al. :Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res 36: 27-32, 2006.
  pubmed

• 23) Fillebeen C, Dehouck B, Benaissa M, Dhennin-Duthille I, Cecchelli R et al. :Tumor necrosis factor-alpha increases lactoferrin transcytosis through the blood-brain barrier. J Neurochem 73:2491-2500, 1999.
  pubmed

• 24) Fillebeen C, Ruchoux MM, Mitchell V, Vincent S, Benaissa M et al. :Lactoferrin is synthcsized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res 96:103-113, 2001.
  pubmed

• 25) Sanchez L, Calvo M, Brock J:Biological role of Lactoferrin. Arch Dis Child 67:657-661, 1992.
  pubmed

• 26) Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM:Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol 23:178-185, 2003.
  pubmed

• 27) Paesano R, Pietropaoli M, Gessani S, Valenti P:The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie 91:44-51, 2009.
  pubmed

• 28) Suzuki YA, Lopez V, Lonnerdal B:Mammalian lactoferrin receptors : structure and function. Cell Mol Life Sci 62:2560-2567, 2005.
  pubmed

• 29) Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi H et al. :Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 74:4137-4142, 1991.
  pubmed

• 30) Gifford JL, Hunter HN, Vogel HJ:Lactoferricin:a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62:2588-2598, 2005.
  pubmed

• 31) Zheng J, Ather JL, Sonstegard TS, Kerr DE:Characterization of the infection-responsive bovine lactoferrin promoter. Gene 353:107-117, 2005.
  pubmed

• 32) Li Y, Limmon GV, Imani F, Teng C:Induction of lactoferrin gene expression by innate immune stimuli in mouse mammary epithelial HC-11 cells. Biochimie 91:58-67, 2009.
  pubmed

• 33) Griesbeck-Zilch B, Meyer HH, Kuhn CH, Schwerin M, Wellnitz O:Staphylococcus aureus and Escherichia coli cause deviating expression profiles of cytokines and lactoferrin messenger ribonucleic acid in mammary epithelial cells. J Dairy Sci 91:2215-2224, 2008.
  pubmed

• 34) Tsuda H, Sekine K, Fujita K, Iigo M:Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies. Biochem Cell Biol 80:131-136, 2002.

• 35) Tsuda H, Ohshima Y, Nomoto H, Fujita K, Matsuda E et al. :Cancer prevention by natural compounds. Drug Metab Pharmacokinet 19:245-263, 2004.

• 36) Bezault J, Bhimani R, Wiprovnick J, Furmanski P: Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 54:2310-2312, 1994.
  pubmed

• 37) Hardiville S, Mariller C, Hoedt E, Benaissa M, Pierce A et al. :Expression of delta-lactoferrin leads to apoptosis via Bax upregulation and the activation of the intrinsic pathway. Cell Biol, 2009(submitted).

• 38) Teng C, Gladwell W, Raphiou I, Liu E:Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals 17:317-323, 2004.
  pubmed

• 39) Benaissa M, Peyrat JP, Hornez L, Mariller C, Mazurier J et al. :Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer 114:299-306, 2005.
  pubmed

• 40) Penco S, Scarfi S, Giovine M, Damonte G, Milo E et al. : Identification of an import signal for, and the nuclear localization of, human lactoferrin. Biotechnol Appl Biochem 34:151-159, 2001.

• 41) He J, Furmanski P:Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721-724, 1995.
  pubmed

• 42) Son KN, Park J, Chung CK, Chung DK, Yu DY et al. : Human lactoferrin activates transcription of IL-1beta gene in mammalian cells. Biochem Biophys Res Comm 290:236-241, 2002.
  pubmed

• 43) Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T et al. :Twenty-five years of research on bovine. Biochimie 91:52-57, 2009.
  pubmed

• 44) Xiao Y, Monitto CL, Minhas K M, Sidransky D: Lactoferrin down-regulates GI cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 10:8683-8686, 2004.

• 45) Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G et al. :Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 74:486-498, 1999.

• 46) Oh SM, Pyo CW, Kim Y, Choi SY:Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. Oncogene 23:8282-8291, 2004.
  pubmed

• 47) Lin TY, Chiou SH, Chen M, Kuo CD:Human lactoferrin exerts bi-directional actions on PC12 cell survival via ERK1/2 pathway. Biochem Biophys Res Comm 337:330-336, 2005.
  pubmed

• 48) Baumrucker CR, Schanbacher F, Shang Y. Green MH:Lactoferrin interaction with retinoid signaling: cell growth and apoptosis in mammary cells. Domest Anim Endocrinol 30:289-303, 2006.
  pubmed

• 49) Lee SH, Park SW, Pyo CW, Yoo NK, Kim J et al. : Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie 91:102-108, 2009.
  pubmed

• 50) Son HJ, Lee SH, Choi SY:Human lactoferrin controls the level of retinoblastoma protein and its activity. Biochem Cell Biol 84:345-350, 2006.
  pubmed

• 51) Katunuma N, Le QT, Murata E, Matsui A, Majima E et al. :A novel apoptosis cascade mediated by lysosomal lactoferrin and its participation in hepatocyte apoptosis induced by D-galactosamine. FEBS Lett 580: 3699-3705, 2006.
  pubmed

• 52) Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H: Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25:1961-1966, 2004.
  pubmed

• 53) Iigo M, Alexander DB, Long N, Xu J, Fukamachi K et al. :Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie 91, 86-101, 2009.
  pubmed

シンポジウム"ラクトフェリンの臨床応用"

P.20 掲載の参考文献

• 1) Kalfas S, Andersson M, Edwardsson S, Forsgren A, Naidu AS:Human lactoferrin binding to Porphyromonas gingivalis, Prevotella intermedia and Prevotella melaninogenica. Oral Microbiol Immunol 6:350-355, 1991.
  pubmed

• 2) Shi Y, Kong W, Nakayama K:Human lactoferrin binds and removes the hemoglobin receptor protein of the periodontopathogen Porphyromonas gingivalis. J Biol Chem 275:30002-30008, 2000.
  pubmed

• 3) Silness J, Loe H:Periodontal disease in pregnancy. H. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22:121-135, 1964.

• 4) Loe H, Silness J:Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 21:533-551, 1963.
  pubmed

• 5) O'Leary TJ, Drake RB, Naylor JE:The plaque control record. J Periodontol 43:38, 1972.

• 6) Ashimoto A, Chen C, Bakker I, Slots J:Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol 11:266-273, 1996.
  pubmed

• 7) 近藤一郎, 小林哲夫, 若林裕之, 山内恒治, 岩附慧二, 吉江弘正:歯周炎患者におけるウシラクトフェリン経口投与の影響. 日歯保存誌 51:281-291, 2008.
  Medical*Online

P.26 掲載の参考文献

• 1) Pischon N, Heng N, Bernimoulin JP, Kleber BM, Willich SN et al.:Obesity, inflammation, and periodontal disease. J Dent Res 86:400-409, 2007.
  pubmed

• 2) Taylor GW, Borgnakke WS:Periodontal disease:associations with diabetes. glycemic control andcomplications. Oral Dis l4:191-203, 2008.

• 3) Ishikado A. Imanaka H, Takeuchi T, Harada E, Makino T:Liposomalization of lactoferrin enhanced it's anti-inflamlnatory effects via oral administrationBiol Pharm Bull 28:1717-1721, 2005.

• 4) 山野栄三, 宮内睦美, 田中栄二, 石角 篤, 今中宏真・ 他:リポソーム化ラクトフェリンの抗炎症作用II. LPS誘導歯周組織破壊モデルにおけるリポソーム化ラクトフェリンの抑制効果. ラクトフェリン2007. 日本医学館, 2007, p226-230.

• 5) McFarlane CG, Reynolds JJ, Meikle MC:The release of interleukin-1β, tumor necrosis factor-α and interferon-γ by cultured peripheral blood mononuclear cells from patients with periodontitis. J periodont Res. 25:207-214, 1990.

• 6) Gustafsson A, Ito H, Asman B, Bergstrom K:Hyperreactive mononuclear cells and neutrophils in chronicperiodontitis. J Clin Periodontol 33:126-129, 2006.

• 7) Mahanonda R, Pichyangkul S:Toll-like receptors and their role in periodontal health and disease. Periodontology 2000 43:41-55, 2007.
  pubmed

• 8) de Wit H, Dokter WH, Koopmans SB, Lummen C, van der Leij M et al.:Regulation of p100(NFKB2)expression in human monocytes in response to inflammatorymediators and lymphokines. Leukimia 12:363-370, 1998.

• 9) Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA. Mattsby-Baltzer I:Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220:83-95, 2002.
  pubmed

P.31 掲載の参考文献

• 1) 厚生労働省:平成18年国民健康・栄養調査結果の概要について. 2008年4月30日.

• 2) 鈴木苗穂, 木川博光・他:ラクトフェリンによる歯周病予防効果:ヒト由来歯肉線維芽細胞に対する影響. ラクトフェリン2007. 日本医学館, 2007, p68-72.

• 3) 鈴木則行・他:2007年度日本栄養・食糧学会要旨集.

• 4) 小野知二・他:2008年度日本肥満学会要旨集.

P.36 掲載の参考文献

• 1) Kuriki K, Tajima K:The increasing incidence of colorectal cancer and the preventive strategy in Japan. Asian Pac J Cancer Prev 7:495-501, 2006.
  pubmed

• 2) Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW et al.:Calcium supplements and colorectal adenomas. Polyp Prevention Study Group. Ann N Y Acad Sci 889:138-145, 1999.

• 3) Ghadirian P, Lacroix A, Maisonneuve P, Perret C, Potvin C et al.:Nutritional factors and colon carcino-ma:acase-control study involving French Canadi-ans in Montreal, Quebec, Canada. Cancer 80:858-864, 1997.

• 4) MacLennan R, Macrae F. Bain C, Battistutta D, Chapuis P et al.:Randomized trial of intake of fat, fiber and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 87:1760-1766, 1995.
  pubmed

• 5) Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H:Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats Carcinogenesis 25:1961-1966, 2004.
  pubmed

• 6) Sekine K, Ushida Y, Kuhara T, Iigo M, Baba-Toriyama H et al.:Inhibition of initiation and early stage development of aberrant crypt foci and en-hanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Lett 121:211-216, 1997.

• 7) Tsuda II, Sekine K Nakamura J, Ushida Y, Kuhara T et al.:Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol 443:273-284, 1998.
  pubmed

• 8) Iigo M, Shimamura M, Matsuda E, Fujita K, Nomoto H et al.:Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa:apossible explanation for inhibition of carcinogenesis and metastasis. Cytokine 25:36-44, 2004.

• 9) Iigo M, Alexander DB, Long N, Xu J, Fukamachi K et al.:Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie 91:86-101, 2009.
  pubmed

• 10) Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T et al.:Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer 111:111-116, 2004.
  pubmed

• 11) 神津隆弘, 斉藤 豊, 松田尚久, 赤須孝之, 飯沼 元・ 他:第65回日本癌学会学術総会 O-779, 2006.

• 12) Ladenheim J, Garcia G, Titzer D et al.:Effect of sulinduc on sporadic colonic polyps. Gastroenterology 108:1083-1087, 1995.
  pubmed

• 13) Wada Y, Yoshida K, Tsutani Y, Shigematsu H, Oeda M et al.:Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep 17:161-167, 2007.
  pubmed

• 14) Wislez M, Antoine M, Rabbe N, Gounant V, Poulot V et al.:Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clin Cancer Res 13:3518-3527, 2007.
  pubmed

• 15) Iigo M, Shimamura M, Hirano S, Nabeshima K, Ohkubo S et al.:Cancer prevention and anti-metastatic effect by oral administration of bovine lactoferrin Carcinogenesis and Modification of Carcinogenesis. (eds. Tanaka T, Tsuda H), Research Signpost, Kerala, India, 2005, p229-242.

• 16) Martins CA, Fonteles MG, Barrett LJ, Guerrant RL:Correlation of lactoferrin with neutrophilic inflammation in body fluids. Clin Diagn Lab Immunol 2:763-765, 1995.
  pubmed

• 17) Damiens E, Mazurier J, el Yazidi I, Masson M, Duthillel et al.:Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelialtumour cells. Biochim Biophys Acta 1402:277-287, 1998.

• 18) Shau H, Kim A, Golub SH:Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 51:343-349. 1992.
  pubmed

• 19) Wang WP, ligo M, Sato J, Sekine K, Adachi I et al.:Activation of intestinal mucosal immunity in tumorbearing mice by lactoferrin. Jpn J Cancer Res 91:1022-1027, 2000.

• 20) Knoernschild HE:Growth rate and malignant potential of colonic polyps:early results. Surg Forum 14:137-138, 1963.
  pubmed

• 21) Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM et al.:Natural history of untreated colonic polyps. Gastroenterology 93(5):1009-1013, 1987.
  pubmed

一般演題およびポスターセッション

P.44 掲載の参考文献

• 1) Lonnerdal B, Iyer S:Lactoferrin:molecular structure and biological function. Annu Rev Nutr 15:93-110, 1995.
  pubmed

• 2) Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T et al.:Twenty-five years of research on bovine lactoferrin applications. Biochimie 91:52-57 2009.
  pubmed

• 3) Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I et al.:Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 61:410-414 2007.
  pubmed

• 4) Berlutti F, Schippa S. Morea C, Sarli S, Perfetto B et al.:Lactoferrin downregulates pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains. Biochem Cell Biol 84:351-357, 2006.
  pubmed

• 5) Yamauchi K, Hiruma M, Yamazaki N, Wakabayashi H, Kuwata H et al.:Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo controlled, double-blind study. Mycoses 43:197-202, 2000.
  pubmed

• 6) Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H et al.:Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C:apilot study. Jpn J Cancer Res 90:367-371. 1999.

• 7) King Jr JC, Cummings GE, Guo N, Trivedi L, Readmond B et al.:Adouble-blind, placebo-control-led, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J pediatr Gastroenterol Nutr 44:245-251, 2007.

• 8) Paesano R, Torcia F. Berlutti F, Pacifici E, Ebano V et al.:Oral administration of lactoferrin increases hemo-globin and total serum iron in pregnant women. Biochem Cell Biol 84:377-380, 2006.

• 9) Koikawa N Nagaoka I, Yamaguchi M, Hamano H, Yamauchi K et al.:Preventive effect of lactoferrin intake on anemia in female long distance runners. Biosci Biotechnol Biochem 72:931-935, 2008.
  pubmed

• 10) Wrackmeyer U, Hansen GH, Seya T, Danielsen EM:Intelectin:Anovel lipid raft-associated protein in the enterocyte brush border. Biochemistry 45:9188-9197, 2006.

• 11) Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa Aet al.:Human intelsctin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 276:23456-23463, 2001.

• 12) Datta R, deSchoolmeester ML, Hedeler C, Paton NW, Brass AM et al.:Identification of novel genes inintestinal tissue that are regulated after infection with an intestinal nematode parasite. Infect Immun 73:4025-4033, 2005.

• 13) Yang RZ, Lee MJ, Hu H, Pray J. Wu HB et al.:Identification of omentin as a novel depot-specific adipokine in human adipose tissue:possible role in modulating insulin action. Am J physiol Endocrinol Metab 290:E1253-E1261, 2006.
  pubmed

• 14) Suzuki YA, Shin K, Lonnerdal B:Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40:15771-15779, 2001.
  pubmed

• 15) Shin K, Wakabayashi H, Yamauchi K, Yaeshima T, Iwatsuki K:Recombinant human intelectin binds bovine lactoferrin and its peptides. Biol Pharm Butl 31:1605-1608. 2008.

• 16) Daugherty DL, Rozema D, Hanson PE, Gellman SH:Artificial chaperone-associated refolding of citrate synthase. J Biol Chem 273:33961-33971, 1998.

• 17) Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi H et al.:Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 74:4137-4142, 1991.
  pubmed

• 18) Root DD, Wang K:Kinetic silver staining and quantification of proteins adsorbed to microtiter plates. Anal Biochem 209:354-359, 1993.
  pubmed

• 19) Suzuki YA, Wong H, Ashida KY, Schryvers AB, Lonnerdal B:The NI domain of human lactoferrin is required for internalization by Caco-2 cells and targeting to the nucleus. Biochemistry 47:10915-10920, 2008.

P.53 掲載の参考文献

• 1) Eming SA, Krieg T, Davidson JM:Inflammation in wound repair:molecular and cellular mechanisms. J Invest Dermatol 127:514-525, 2007.
  pubmed

• 2) Asai J, Takenaka H, Ichihashi K, Ueda E, Katoh N et al.:Successful treatment of diabetic gangrene with topical application of a mixture of peripheral blood mononuclear cells and basic fibroblast growth factor. J Dermatol 33:349-352, 2006.
  pubmed

• 3) Tanaka E, Ase K, Okuda T, Okumura M, Nogimori K:Mechanism of acceleration of wound healing by basic fibroblast growth factor in genetically diabetic mice. Biol Pharm Bull 19:1141-1148, 1996.

• 4) Suzuki YA, Shin K, Lonnerdal B:Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40:15771-15779, 2001.
  pubmed

• 5) Takayama Y, Mizumachi K:Effects of lactoferrin on collagen gel contractile activity and myosin light chain phosphorylation in human fibroblasts. FEBS Letters 508:111-116, 2001.
  pubmed

• 6) Takayama Y, Takezawa T:Lactoferrin promotes collagen gel contractile activity of fibroblasts mediated by lipoprotein receptors. Biochem Cell Biol 84:268-274, 2006.
  pubmed

• 7) Braiman-Wiksman L, Solomonik I, Spira R, Tennenbaum T:Novel insights into wound healing sequence of events. Toxicol Pathol 35:767-779, 2007.
  pubmed

• 8) Martin P:Wound healing-aiming for perfect skin regeneration. Science 276:75-81, 1997.
  pubmed

• 9) Singer AJ, Clark RA:Cutaneous wound healing. N Engl J Med 341:738-746. 1999.
  pubmed

• 10) Brown DL Kao WW, Greenhalgh DG:Apoptosis down-regulates inflammation under the advancing epithelial wound edge:delayed patterns in diabetes and improvement with topical growth factors. Surgery 121:372-380, 1997.
  pubmed

• 11) Bednarz J, Thalmann-Goetsch A, Richard G, Engelmann K:Differences in proliferation and migration of corneal endothelial cells [correction of epithelial cells] after cell transplantation in vitro. Ger J Ophthalmol 5:127-131, 1996.

• 12) Thalmann-Goetsch A, Engelmann K, Bednarz J:Comparative study on the effects of different growth factors on migration of bovine corneal endothelial cells during wound healing. Acta Ophthalmol Scand 75:490-495. 1997.
  pubmed

• 13) Etscheid M, Beer N, Dodt J:The hyaluronan-binding protease upregulates ERK1/2 and PI3K/Akt signalling pathways in fibroblasts and stimulates cell proliferation and migration. Cellular Signalling 17:1486-1494, 2005.
  pubmed

• 14) Schramek H:MAP kinases:from intracellular signals to physiology and disease. News Physiol Sci 17:62-67, 2002.
  pubmed

• 15) Blenis J:Signal transduction via the MAP kinases:proceed at your own RSK. Proc Natl Acad Sci USA 90:5889-5892, 1993.
  pubmed

• 16) Brunet A, Pouyssegur J:Mammalian MAP kinase modules:how to transduce specific signals. EssaysBiochem 32:1-16, 1997.
  pubmed

• 17) Tomic-Canic M, Komine M, Freedberg IM, Blumenberg M:Epidermal signal transduction and transcriptio factor activation in activated keratinocytes. J Dermatol Sci 17:167-181, 1998.
  pubmed

• 18) Nebreda AR, Porras A:p38 MAP kinases:beyond the stress response. Trends Biochem Sci 25:257-260. 2000.
  pubmed

• 19) Werry TD, Christopoulos A, Sexton PM:Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 12:1683-1702, 2006.
  pubmed

• 20) Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T:Protein kinase C family:on the crossroads of cell signaling in skin and tumorepithelium. J Cancer Res Clin Oncol 133:793-808, 2007.
  pubmed

• 21) Yamamura S, Nelson PR, Kent KC:Role of proteinkinase C in attachment, spreading, and migration ofhuman endothelial cells. J Surg Res 63:349-354, 1996.

• 22) Itoh H, Yamamura S, Ware JA, Zhuang S, Mii S et al.:Differential effects of protein kinase C on human vascular smooth muscle cell proliferation and migration Am J Physiol Heart Circ Physiol 281:H359-370, 2001.
  pubmed

• 23) Leszczynski D, Joenvaara S, Foegh ML:Proteinkinase C-alpha regulates proliferation but not apoptosis in rat coronary vascular smooth muscle cells. Life Sci 58:599-606, 1996.

• 24) Tang S, Morgan KG, Parker C, Ware JA:Requirement for protein kinase C theta for cell cycle progression and formation of actin stress fibers and filopodia in vascular endothelial cells. J Biol Chem 272:28704-28711, 1997.
  pubmed

• 25) Wyatt TA, Ito H, Veys TJ, Spurzem JR:Stimulation of protein kinase C activity by tumor necrosis factoralpha in bovine bronchial epithelial cells. Am J physiol 273:L1007-1012, 1997.
  pubmed

• 26) Skaletz-Rorowski A, Waltenberger J, Muller JG, Pawlus E, Pinkernell K et al.:Protein kinase C mediates basic fibroblast growth factor-induced proliferation through mitogen-activated protein kinase in coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 19:1608-1614, 1999.

• 27) Schonwasser DC, Marais RM, Marshall CJ, Parker PJ:Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel. and atypical protein kinase C isotypes. Mol Cell Biol 18:790-798, 1998.
  pubmed

• 28) Marais R, Light Y. Mason C, Paterson H, Olson MF et al.:Requirement of Ras-GTP-Raf complexes foractivation of Raf-1 by protein kinase C. Science 280:109-112, 1998.
  pubmed

• 29) Hundson LG, McCawley LJ:Contributions of the epidermal growth factor receptor to keratinocyte motility. Microsc. Res Tech 43:444-455, 1998.

• 30) De Giorgi V. Sestini S, Massi D, Ghersetich I, Lotti T:Keratinocyte growth factor receptors. Dermatol Clin 25:477-485. 2007.
  pubmed

• 31) Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A et al.:Localization of matrix metalloproteinase 3(stromelysin)in osteoarthritic cartilage and synovium. Lab Invest 66:680-690, 1992.
  pubmed

• 32) Araya J, Maruyama M, Sassa K, Fujita T, Hayashi R, et al.:Ionizing radiation enhances matrix metalloproteinase-2 production in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 280:L30-38 2001.
  pubmed

• 33) Persson L, Bergstrom J, Gustafsson A:Effect of tobacco smoking on neutrophil activity following periodontal surgery. J Peeriodontol 74:1475-1482, 2003.
  pubmed

• 34) Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N et al.:Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113-3119, 2001.
  pubmed

• 35) Rha SY, Jeung HC, Roh JK, Kim JJ, Noh SH et al.:Biological phenotype determination with ex vivo model in gastric cancer for matrix-metall oproteinase inhibitor treatment. Int J Mol Med 10:251-256, 2002.

• 36) Liu J, Tsao MS, Pagura M, Shalinsky DR, Khoka R, et al.:Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model Lung Cancer 42:335-344, 2003.

• 37) Baker EA, Leaper DJ:Proteinases, their inhibitors, and cytokine profiles in acute wound fluid. Wound Repair Regen 8:392-398, 2000.
  pubmed

• 38) Wang L, Luo J, He S.:Induction of MMP-9 release from human dermal fibroblasts by thrombin:involvement of JAK/STAT3 signaling pathway in MMP-9release. BMC Cell Biology 8:14, 2007.
  pubmed

• 39) O'toole EA, Van Koningsveld R, Chen M, Woodley DT:Hypoxia induces epidermal keratinocyte matrix metalloproteinase-9 secretion via the protein kinase C pathway. J Cell Physiol 214:47-55, 2008.
  pubmed

• 40) Cohen M, Meisser A, Haenggeli L, Bischof P:Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells. Mol Human Reprod 12:225-232, 2006.
  pubmed

P.61 掲載の参考文献

• 1) Watanabe T:HTLV-1-associated diseases. Int J Hematol 66(3):257-278, 1997.
  pubmed

• 2) Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H:Adult T-cell leukemia:clinical and hematological features of 16 cases. Blood 50(3):481-492, 1977.
  pubmed

• 3) Yoshida M, Miyoshi I, Hinuma Y:Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79(6):2031-2035, 1982.
  pubmed

• 4) Okochi K Sato H, Hinuma Y:Aretrospective study on transmission of adult T cell leukemia virus by blood transfusion:seroconversion in recipients. Vox Sang 46(5:245-253, 1984.

• 5) Kinoshita K, Amagasaki T, Hino S, Doi H, Yamanouchi K et al.:Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res 78(7):674-680, 1987.
  pubmed

• 6) Sugiyama H, Doi H, Yamaguchi K, Tsuji Y, Miyamoto Tet al.:Significance of postnatal mother-to-child transmission of human T-lymphotropic virus type-I on the development of adult T-cell leukemia/lympho-ma. J Med Virol 20:253-260, 1986.

• 7) Wakabayashi H, Kurokawa M, Shin K, Teraguchi S, Tamura Y et al.:Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type I infection of mice. Biosci Biotechnol Biochem 68(3):537-544, 2004.
  pubmed

• 8) Kuhara T, Yamauchi K, Tamura Y, Okamura H:Oral administration of lactoferrin increases NK cell activitvy in mice via increased production of I-18 and type I IFN in the small intestine J Interferon Cytokine Res 26(7):489-499, 2006.
  pubmed

• 9) Fang J, Kushida S, Feng R, Tanaka M, Kawamura T et al.:Transmission of human T-cell leukemia virus type 1 to mice. J Virol 72(5):3952-3957, 1998.
  pubmed

• 10) Tanaka M, Sun B, Fang J, Nitta T, Yoshida T et al.:Human T-cell leukemia virus type 1(HTLV-1)infection of mice:Proliferation of cell clones with integrat-ed HTLV-I provirus in lymphoid organs. J Virol 75 (9):4420-4423, 2001.

• 11) Nitta T, Tanaka M, Sun B, Hanai S, Miwa M:The genetic background as a determinant of human T-cell leukemia virus type I proviral load. Biochem Biophys Res Commun 309(1):161-165, 2003.
  pubmed

• 12) Moriuchi M, Moriuchi H:Amilk protein lactoferrin enhances human T cell leukemia virus type I and supPresses HIV-1 infection. J Immunol 166(6):4231-4236, 2001.
  pubmed

P.68 掲載の参考文献

• 1) Kato N, Ikeda M, Mizutani T, Sugiyama K, Noguchi M et al.:Replication of hepatitis C virus in cultured non-neoplas tic human hepatocytes. JPn J Cancer Res 87:787-792, 1996.

• 2) Ikeda M, Sugiyama K, Mizutani T, Tanaka K, Kato N et al.:Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res 56:157-167, 1998.
  pubmed

• 3) Ikeda M, Sugiyama K, Tanaka T. Tanaka K, Kato N et al.:Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245:549-553, 1998.
  pubmed

• 4) Ikeda M, Nozaki A, Tanaka K, Shimotohno K, Kato N et al.:Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 66:51-63, 2000.
  pubmed

• 5) Inudoh M, Tanaka T, Hijikata M, Kato N, Shimotohno K et al.:Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells. Vaccine 14:1590-1596, 1996.
  pubmed

• 6) Nozaki A, Ikeda M, Naganuma A, Tanaka K, Kato N et al.:Identification of lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278:10162-10173, 2003.
  pubmed

• 7) Abe K, Nozaki A, Ikeda M. Tanaka K. Kato N et al.:Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol Immunol 51:117-125. 2007.
  pubmed

• 8) Tanaka K, Ikeda M, Nozaki A, Kato N. Tsuda H et al.:Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C. Jpn J Cancer Res 90:367-371, 1999.
  pubmed

• 9) Okada S, Tanaka K, Sato T, Ueno H, Saito S et al.: Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 93:1063-1069, 2002.
  pubmed

• 10) Ueno H, Sato T, Yamamoto S, Tanaka K, Ohkawa S et al.:Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci 97:1105-1110, 2006.
  pubmed

• 11) Beleid R, Douglas D, Kneteman N. Kaur K:Helical peptides derived from lactoferrin bind hepatitis C virus envelope protein E2. Chem Biol Drug Des 72:436-443, 2008.
  pubmed

• 12) Hara K, Ikeda M, Numata K, Kato N, Tanaka K et al.:Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 24:228-235. 2002.
  pubmed

P.73 掲載の参考文献

• 1) Masson PL, Heremans JF, Schonne E:Lactoferrin, an iron-binding Protein in neutrophilic leukocytes. J Exp Med 130:643-658, 1969.
  pubmed

• 2) Aisen P, Listowsky I:Iron transport and storage proteins. Annu Rev Biochem 49:357-393, 1980.
  pubmed

• 3) Sandomirsky BP, Galchenko SE, Galchenko KS:Antioxidative properties of lactoferrin from bovine colostrurn before and after its lyophization. Cryo Letters 24:275-280, 2003.
  pubmed

• 4) Ishikado A, Imakana H, Takeuchi T, Harada E, Makino T:Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration. Biol Pharm Bull 28:1717-1721, 2005.

• 5) Ikeda M, Sugiyama K, Tanaka T, Tanaka T, Tanaka K et al.:Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245:549-553. 1998.
  pubmed

• 6) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. lnfect Immun 28:893-898, 1980.
  pubmed

• 7) Yamaguchi K, Wakagayashi H, Hashimoto S, Teraguchi S, Hayasawa H et al.:Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443:261-265, 1998.

• 8) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Novel central function of milk-derived lactoferrin on antinociception mediated by μ-opioid receptor in the rat spinal cord. Brain Res 965:239-245, 2003.

• 9) Veronese FM, Pasut G:PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-1458, 2005.
  pubmed

• 10) Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY:Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 256:H589-H593, 1989.
  pubmed

• 11) Matsushima A, Sasaki H. Kodera Y, Inada Y:Reduction of immunoreactivity of bovine serum albumin conjugated with polyethylene glycol(PEG)in relation to its esterase activity. Biochem Int 26:485-490, 1992.
  pubmed

• 12) Kodera Y. Tanaka H, Matsushima A, Inada Y:Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride. Biochem Biophys Res Commun 184:144-148, 1992.
  pubmed

• 13) Bailon P. Palleroni A, Schaffer CA, Spence CL, Fung WJ et al.:Rational design of a potent, long-lasting form of interform:a40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12, 195-202. 2001.

• 14) Wang YS, Youngster S, Grace M, Bausch J, Bordens R et al.:Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Delivery Rev 54:547-570, 2002.

• 15) Nojima Y, Suzuki Y, Iguchi K, Shiga T, lwata A et al.:Development of poly(ethylene glycol)conjugated lactoferrin for oral administration. Bioconjugate Chem 19:2253-2259, 2008.

• 16) 野島康弘, 鈴木庸介, 志賀恒雄, 岩田 彩, 藤本友仁・他:医薬品への展開を目指したポリエチレングリコール修飾ラクトフェリンの開発. ラクトフェリン2007. 日本医学館. 2007, p43-49.

• 17) Korkolopoulou PA, Konstantinidou AE, Patsouris ES, Christodoulou PN, Thomos-Tsagli EA et al.:Detection of apoptotic cells in archival tissue from diffuseastrocytomas using a monoclonal antibody to singlestranded DNA. J Pathol 193:377-382, 2001.

• 18) McAbee DD, Esbensen K:Binding and endocytosis of apo-and holo-lactoferrin by isolated rat hepatocytes. J Biol Chem 266:23624-23631, 1991.
  pubmed

• 19) Suzuki YA, Lonnerdal B:Characterization of mammalian receptors for lactoferrin. Biochem Cell Biol 80:75-80, 2002.
  pubmed

• 20) Roseng L, Tolleshaung H, Berg T:Uptake, intercelular transport, and degradation of polyethylene glycolmodified asialofetuin in hepatocytes. J Biol Chem 267:22987-22993. 1992.

• 21) Caliceti P, Schiavon O. Veronese FM:Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjugate Chem 10:638-646, 1999.

• 22) Shi J, Aisaki K, Ikawa Y, Wake K:Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 153:515-525, 1998.
  pubmed

• 23) Sun F, Hamagawa E, Tsutsui C, Ono Y, Ogiri Y et al.:Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. Biochim Biophys Acta 1535:186-191, 2001.
  pubmed

P.78 掲載の参考文献

• 1) Wakabayashi H, Abe S, Teraguchi S, Hayasawa H, Yamaguchi H:Inhibition of hyphal growth of azole-resistant strains of Candida a/bicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob Agents Chemother 42:1587-159. 1, 1998.

• 2) Takakura N Wakabayashi H, Ishibashi H. Teraguchi S, Tamura Y et al.:Oral lactoferrin treatment of experimental oral candidiasis in mice. Antimicrob Agents Chemother 47:2619-2623, 2003.
  pubmed

• 3) Kalmar JR, Arnold RR:Killing of Actinobacillus actinomycetemcomitans by human lactoferrin. Infect Immun 56:2552-2557, 1988.
  pubmed

• 4) Aguilera O, Andr6s MT, Heath J, Fierro JF, Douglas CWI:Evaluation of the antimicrobial effect of lacto-ferrin on Porphyromonas gingivalis, Prevotlla inter-media and Prez, otella, nigrescens. FEMS Immunol Med Microbiol 21:29-36, 1998.

• 5) 近藤一郎, 小林哲夫, 若林裕之, 山内恒治, 岩附慧二・ 他:歯周炎患者におけるウシラクトフェリン経口投与の影響. 日歯保存誌 51:281-291, 2008.
  Medical*Online

• 6) Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K et al.:Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother, 2009, in press

• 7) Singh PK, Parsek MR, Greenberg EP, Welsh MJ:A component of innate immunity prevents bacterial biofilm development. Nature 417:552-555, 2002.
  pubmed

• 8) O'May CY, Sanderson K Roddam LF, Kirov SM Reid DW:Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. J Med Microbiol 58:765-773, 2009.
  pubmed

• 9) Alugupalli KR, Kalfas S, Edwardsson S, Forsgren A, Arnold RR et al.:Effect of lactoferrin on interaction of Prevotella intermiedia with plasma and subepithelial matrix proteins. Oral Microbiol lmmunol 9:174-179., 1994.
  pubmed

P.83 掲載の参考文献

• 1) Garrison SW, Nichols FC:LPS-elicited secretory responses in monocytes:altered release of PGE2 IL-1β in patients with adult periodontitis. J periodontal Res 24:88-95, 1989.

• 2) Lindemann RA. Economou JS, Rothermel H:Production of interleukin-1 and tumor necrosis factor bv human peripheralmonocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dent Res 67:1131-1136, 1988.

• 3) Masson PL, Heremans JF:Lactoferrin in milk from different species. Comp Biochem Physiol 39:119-129, 1971.
  pubmed

• 4) Ward PP, Paz E, Conneely OM:Multifunctional roles of lactoferrin:acritical overview. Cell Mol Life Sci 62:2540-2548, 2005.

• 5) 日本食品添加物協会技術委員会編:食品添加物表示ポケットブック. 日本食品添加物協会. 1997.

• 6) Troost FJ, Steijns J, Saris wH, Brummer RJ:Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr 131:2101-2104, 2001.
  pubmed

• 7) 山野栄三, 宮内睦美, 田中栄二, 石角 篤, 今中宏真・ 他:リポソーム化ラクトフェリンの抗炎症作用:II. LPS誘導歯周組織破壊モデルにおけるリポソーム化ラクトフェリンの抑制効果. ラクトフェリン2007. 日本医学館, 2007, p129-133.

• 8) Ishikado A, Imanaka H, Takeuchi T, Harada E Makino T:Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration. Biol Pharm Bull 28(9):1717-1721, 2005.

• 9) 菰田衛:レシチン-その基礎と応用, 幸書房, 1991.

• 10) 食品化学新聞社編集:世界の食品添加物. 食品化学新聞社. 1989.

• 11) Na YJ, Han SB, Kang JS, Yoon YD, Park SK et al.:Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. Int Immunopharmacol 4:1187-1199, 1996.

• 12) Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I:Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220:83-95, 2002.
  pubmed

P.88 掲載の参考文献

• 1) ラクトフェリン2007. 日本医学館, 2007.

• 2) Nishimura F, Iwamoto Y, Soga Y:The periodontal host response with diabetes. Periodontol 2000 43:245-253. 2007.
  pubmed

• 3) Zimecki M, Miedzybrodzki R, Szymaniec S:Oral treatment of rats with bovine lactoferrin inhibits carrageenan-induced inflammation; correlation with decreased cytokine production. Arch Immunol Ther Exp(Warsz)46:361-365, 1998.
  pubmed

• 4) Lorget F, Clough J, Oliveira M, Daury MC et al.:Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun 296:261-266, 2002.
  pubmed

• 5) Zimecki M, Mazurier J, Spik G, Kapp JA:Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 88:122-127, 1995.

• 6) Shimizu K, Matsuzawa H, Okada K, Tazume S et al.:Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity. Arch Virol 141:1875-1889, 1996.

• 7) Hayashida K, Kaneko T, Takeuchi T, Shimizu H et al.:Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 66:149-154, 2004.
  pubmed

• 8) Grey A, Banovic T, Zhu Q, Watson M et al.:The low-density lipoprotein receptor related protein I is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268-2278, 2004.

• 9) Takayama Y, Takezawa T:Lactoferrin promotes collagen gel contractile activity of fibroblasts mediated by lipoprotein receptors. Biochem Cell Biol 84:268-274, 2006.
  pubmed

• 10) Oh SM, Lee SH, Lee BJ, Pyo CW et al. l A distinct role of neutrophil lactoferrin in RelA/p65 phosphorylation on Ser536 by recruiting TNF receptor-associated factors to IkappaB kinase signaling complex. J Immunol 179:5686-5692, 2007.

• 11) Haversen L, Ohlsson BG, Hahn-Zoric M Hanson LA, Mattsby-Baltzer I:Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220:83-95, 2002.
  pubmed

P.94 掲載の参考文献

• 1) Siebert PD, Huang BC:Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci USA 94:2198-2203, 1997.
  pubmed

• 2) Benaissa M, Peyrat J, Hornez L, Mariller C, Mazurier J et al.:Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer 114:299-306, 2004.

• 3) Liu D, Wang X, Zhang Z, Teng CT:An intronic alternative promoter of the human lactoferrin gene is activated by Ets. Biochem. Biophys. Res Commun 301 :472-479, 2003.
  pubmed

• 4) Pierce A. Hardiviile S, Hoedt E, Mariller C, Benaissa M et al.:Structure-function of lactoferrin isoforms. The Lactoferrin 2009. Nihon Igakukan, Tokyo, 2009, p3-11.

• 5) Breton M, Mariller C, Benaissa M, Caillaux K, Browaeys E et al.:Expression of delta-lactoferrin induces cell cycle arrest. Biometals 17:325-329, 2004.
  pubmed

• 6) Mariller C, Benaissa M, Hardiville S, Breton M, Pradelle G et al.:Human delta-lactoferrin is a transcription factor that enhances Skp1 (S-phase kinase-associated protein) gene expression. FEBS J 274:2038-2053, 2007.
  pubmed

• 7) Hardiville S, Mariller C, Hoedt E, Benaissa M, Pierce A et al.:Expression of delta-lactoferrin leads to apoptosis via Bax upregulation and the activation of the intrinsic pathway. Cell Biol, 2009 (submitted).

• 8) Ang XL, Harper JW:Interwoven ubiquitination oscillators and control of cell cycle transitions. Sci STKE 242:pe31, 2004.
  pubmed

• 9) Krek W:Proteolysis and the G1-S transition:the SCF connection. Curr Opin Genet Dev 8:36-42, 1998.
  pubmed

• 10) Hardiville S, Benaissa M, Mariller C, Hoedt E, Pierce A et al.:The stability of the transcription factor ΔLf is controlled by the O-GlcNAc interplay. J Cell Biol, 2009 (submitted).

• 11) Hart GW, Kreppel LK, Comer FI, Arnold CS, Snow DM et al.:O-GlcNAcylation of key nuclear and cytoskeletal proteins:reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology 6:711-716, 1996.

• 12) Mariller C, Hardiville S, Hoedt E, Benaissa M, Mazurier J et al.:Proteomic approach to the identification of novel delta-lactoferrin target genes:Characterization of DcpS, an RNA scavenger decapping enzyme. Biochimie 91:109-122, 2009.

• 13) Tanahashi N, Tsurumi C, Tamura T, Tanaka K: Molecular structure of 20S and 26S proteasomes. Enzyme Protein 47:241-251, 1993.
  pubmed

• 14) Kooi CWV, Ohi MD, Rosenberg JA, Oldham ML, Newcomer ME et al.:The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases. Biochemistry 45:121-130, 2006.

• 15) Bedard K, Szabo E, Michalak M, Opas M:Cellular functions of endoplasmic reticulum chaperones calreticulin, calnexin, and ERp57. Int Rev Cytol 245:91-121, 2005.
  pubmed

• 16) Dunn AY, Melville MW, Frydman J:Review:cellular substrates of the eukaryotic chaperonin TRiC/CCT. J Struct Biol 135:176-184, 2001.
  pubmed

• 17) Roychoudhury P, Paul RR, Chowdhury R, Chaudhuri K:HnRNP E2 is downregulated in human oral cancer cells and the overexpression of hnRNP E2 induces apoptosis. Mol Carcinog 46:198-207, 2007.
  pubmed

• 18) Grantham J, Brackley KI, Willison KR:Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp Cell Res 312:2309-2324, 2006.
  pubmed

• 19) Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C et al.:Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol 210:351-357, 2006.
  pubmed

• 20) Lu X, Legerski RJ:The Prp19/Pso4 core complex undergoes ubiquitylation and structural alterations in response to DNA damage. Biochem Biophys Res Commun 354:968-974, 2007.
  pubmed

• 21) Chan S, Cheng S:The Prp19-associated complex is required for specifying interactions of U5 and U6 with pre-mRNA during spliceosome activation. J Biol Chem 280:31190-31199, 2005.
  pubmed

• 22) Liu X, Mertz, JE:HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression. Genes Dev 9:1766-1780, 1995.
  pubmed

• 23) Makeyev AV, Liebhaber SA:The poly(C)-binding proteins:a multiplicity of fumctions and a search for mechanisms. RNA 8:265-278, 2002.

• 24) Liu H, Rodgers ND, Jiao X, Kiledjian M:The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases. EMBO J 21:4699-4708, 2002.
  pubmed

• 25) Coller J, Parker R:Eukaryotic mRNA decapping. Annu Rev Biochem 73:861-890, 2004.
  pubmed

• 26) Liu H, Kiledjian M:Decapping the message:a beginning or an end. Biochem Soc Trans 34:35-38, 2006.
  pubmed

• 27) Shen V, Liu H, Liu S, Jiao X, Kiledjian M:DcpS scavenger decapping enzyme can modulate pre-mRNA splicing. RNA 14:1132-1142, 2008.

• 28) van Hoof A, Frischmeyer PA, Dietz H C, Parker R:Exosome-mediated recognition and degradation of mRNAs lacking a termination codon. Science 295:2262-2264, 2002.
  pubmed

• 29) van Dijk E, Hir HL, Seraphin B:DcpS can act in the 5'-3'mRNA decay pathway in addition to the 3'-5' pathway. Proc Natl Acad Sci USA 100:12081-12086, 2003.

• 30) Nuss DL, Furuichi Y, Koch G, Shatkin AJ:Detection in HeLa cell extracts of a 7-methyl guanosine specific enzyme activity that cleaves m7GpppNm. Cell 6:21-27, 1975.
  pubmed

P.100 掲載の参考文献

• 1) Lambert LA, Perri H, Meehan TJ:Evolution of duplications in the transferrin family of proteins. Comp Biochem Physiol B Biochem Mol Biol 140(1):11-25. 2005.
  pubmed

• 2) Lambert LA, Perri II. Ilalbrooks PJ, Mason AB:Evolution of the transferrin family:conservation of residues associated with iron and anion binding. Comp Biochem Physiol B Biochem Mol Biol 142(2):129-141, 2005.

• 3) 市村 薫, 木原 裕:トランスフェリン-構造と金属結合の協同性-. 蛋白質・核酸・酵素 39(14):2297-2309, 1994.

• 4) 第1回ラクトフェリンフォ-ラム実行委員会(編):特集ラクトフェリンフォ-ラム〜基礎から応用への架け橋〜. ミルクサイエンス 53(4), 2004.

• 5) ラクトフェリン2007. 日本医学館, 2007.

• 6) Toinita M, Takase M Bellamy W, Shimamura S:A review:the active peptide of lactoferrin. Acta Paediatr Jpn 36(5):585-591. 1994.

• 7) Kawai K, Shimazaki K, Higuchi H. Nagahata H:Antibacterial activity of bovine lactoferrin hydrolysate against mastitis pathogens and its effect on superoxide production of bovine neutrophils. Zoono-ses Public Health 54(3-4):160-164. 2007.

• 8) Kimura M, Nam MS, Ohkouchi Y, Shimazaki K, Yu DY:Antimicrobial peptide of Korean native goat lactoferrin and identification of the part essential for this activity. Biochem. Biophys Res Commun 268(2):333-336, 2000.
  pubmed

• 9) Yamashoji S, Takeda M:Menadione-catalyzed luminol chemiluminescent assay for the viability of Escherichia coli ATCC 25922. Microbiol lmmunol 45 (11):737-741, 2001.
  pubmed

• 10) 浜口浩三:改訂蛋白質機能の分子論. 学会出版センター, 1990.

• 11) 平田陸正:哺乳類がつくる抗菌蛋白質(CAP 18)のリポ多糖中和活性と生体防御. 蛋白質・核酸・酵素 46(4):575-581, 2001.

• 12) Jenssen H. Hamill P, Hancock RE:Peptide antimicrobial agents. Clin Microbiol Rev 19(3):491-511, 2006.

• 13) 園元謙二, 指原紀宏:乳酸菌のバクテリオシンの構造と作用機構. 蛋白質・核酸・酵素 46(4):323-332, 2001.

• 14) van der Kraan MI, Groenink J, Nazmi K, Veerman EC, Bolscher JG:Lactoferrampin:anovel antimicrobial peptide in the Nl-domain of bovine lactoferrin. Peptides 25(2):177-183, 2004.

• 15) Viejo-Diaz M, Andres MT, Fierro JF:Different anti-Candida activities of two human lactoferrin-derived peptides. Lfpep and kaliocin-1. Antimicrob Agents Chemother 49(7):2583-2588, 2005.
  pubmed

• 16) Ivan Lopez Exposito, Isidra Recio:Antibacterial activity of peptides and folding variants from milk proteins. Int Dairy J 16(11):1294-1305, 2006.

• 17) Umeyama M, Kira A, Nishimura K, Naito A:Interactions of bovine lactoferricin with acidic phospholipid bilayers and its antimicrobial activity as studied by solid-state NMR. Biochim Biophys Acta 1758(9):1523-1528, 2006.
  pubmed

P.107 掲載の参考文献

• 1) 島崎敬一:ラクトフェリンの多機能性をどう説明するか. ミルクサイエンス 53(4):365-368. 2004.

• 2) 久原徹哉:ラクトフェリン経口摂取によるNK細胞活性増強とそのメカニズム. Foods Food Ingred J Jpn (食品・食品添加物研究誌)211(9):754-762, 2006.

• 3) Miyazawa K. Mantel C. Lu L. Morrison DC. Broxmeyer HE:Lactoferrin-lipopolysaccharide interactions. Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J Immunol 146 (2):723-729, 1991.
  pubmed

• 4) Shimazaki K. Tazume T. Uji K. Tanaka M. Shimo-Oka T et al.:Properties of a heparin-binding peptide derived from bovine lactoferrin. J Dairy Sci 81(11):2841-2849, 1998.
  pubmed

• 5) Qiu J. Hendrixson DR. Baker EN. Murphy TF. St Geme JW 3rd. Plaut AG:Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci USA 95(21):12641-12646, 1998.
  pubmed

• 6) Plaut AG. Qiu J. St Geme. JW 3rd:Human lactoferrin proteolytic activity I analysis of the cleaved region in the IgA protease of Haemophilus influenzae. Vaccine 19(Suppl 1):S148-S152, 2000.

• 7) Massucci MT. Giansanti F. Di NG. Turacchio M. Giardi MFB. et al.:Proteolytic activity of bovine lactoferrin. Biometals 17(3):249-255, 2004.

• 8) Kanyshkova TG. Babina SE. Semenov DV. Isaeva N. Vlassov AV. et al.:Multiple enzymic activities of human milk lactoferrin. Eur J Biochem 270(16):3353-3361, 2003.
  pubmed

• 9) Pejler G:Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase:characterization of the binding of heparin to lactoferrin. Biochem J 320(Pt 3):897-903, 1996.

• 10) Elrod KC. Moore WR. Abraham WM. Tanaka RD:Lactoferrin. a potent tryptase inhibitor. abolishes late-phase airway responses in allergic sheep. Am J Respir Crit Care Med 156(2 Pt 1):375-381, 1997.

• 11) 藤原三知雄, 谷川紘三, 川上 浩, 大槻健蔵:ラクトフェリン結合性protein(LF-BP)の生理機能解析からのLFの生理機能. ミルクサイエンス 53(4):320-322. 2004.

• 12) Shimazaki K. Tanaka T. Kon H. Oota K. Kawaguchi A. et al.:Separation and characterization of the C-terminal half molecule of bovine lactoferrin. J Dairy Sci 76(4):946-955, 1993.

• 13) Shimazaki K. Nam MS. Harakawa S. Tanaka T. Omata Y, et al.:Monoclonal antibody against bovine lactoferricin and its epitopic site. J Vet Med Sci 58(12)1227-1229, 1996.

• 14) Nam MS. Kamio M. Shimazaki K. Harakawa S. Tanaka T. et al.:Fine structure of epitopic sites in human and bovine lactoferrin recognized by anti-bovine lactoferrin C-lobe monoclonal antibody. Food Agri Immunol 14(2)139-146, 2002.

• 15) Kijlstra A. Jeurissen SH. Koning KM:Lactoferrin levels in normal human tears. Br J Ophthalmol 67 (3):199-202, 1983.
  pubmed

• 16) Kai K. Komine Y. Komine K. Asai. K. Kuroishi T. et al.:Effects of bovine lactoferrin by the intramammary infusion in cows with staphylococcal mastitis during the early non-lactating Period. J Vet Med Sci 64(10):873-878, 2002.
  pubmed

• 17) Rajan GH. Morris CA. Carruthers VR. Wilkins RJ. Wheeler TT:The relative abundance of a salivary protein. bSP30. is correlated with susceptibility to bloat in cattle herds selected for high or low bloat susceptibility. Anim Genet 27(6):407-414, 1996.
  pubmed

• 18) Wheeler TT. Haigh BJ. McCracken JY. Wilkins RJ. Morris CA. et al.:The BSP30 salivary proteins from cattle. LUNX/PLUNC and von Ebner's minor salivary gland protein are members of the PSP/LBP superfamily of proteins. Biochim Biophys Acta 1579(2-3):92-100. 2002.

• 19) Haigh B. Hood K. Broadhurst M. Medele S. Callaghan M, et al.:The bovine salivary proteins BSP30a and BSP30b are independently expressed BPI-like proteins with anti-Pseudomonas activity. Mol Immunol 45(7):1944-1951, 2008.
  pubmed

P.114 掲載の参考文献

• 1) Fiat AM. Levy-Toledano S. Caen JP. Jolles P:Biologically active peptides of casein and lactotrans-ferrin implicated in platelet function. J Dairy Res 56:351-355, 1989.

• 2) Tomita M. Bellamy W. Takase M. Yamauchi K. Wakabayashi H et al.:Potent antibacterial peptides generated by pepsindigestion of bovine lactoferrin. J Dairy Sci 74:4137-4142, 1991.

• 3) Kangawa K Minamino N. Fukuda A. Matsuo H:Neuromedin K:anovel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun ll4:533-540, 1983.

• 4) Minamino N. Kangawa K. Matsuo H:Neuromedin B:anovel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 114:541-548, 1983.

• 5) Minamino N. Kangawa K. Matsuo H:Neuromedin C:abombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 119:14-20.
  pubmed

• 6) Minamino N. Kangawa K. Fukuda A. Matsuo H:Neuromedin L:anovel mammalian tachykinin identified in porcine spinal cord. Neuropeptides 4:157-166. 1984.

• 7) Minamino N. Kangawa K. Matsuo H:Neuromedin N:anovel neurotensin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 122:542-549, 1984.

• 8) Minamino N. Kangawa K. Matsuo H:Neuromedin U-8and U-25:novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem Biophys Res Commun 130:1078-1085 1985.

• 9) Chiba H. Tani F. Yoshikawa M:Opioid antagonist peptides derived from κ-casein. J Dairy Res 56:363-366, 1989.

• 10) Takahashi M. Moriguchi S. Minami T. Suganuma H. Yoshikawa M et al.:Albutensin A. an ileum-contracting peptlde derived from serum albumin. acts through both receptors for complements C3a and C5a. Lett Peptide Sci 5:29-35, 1998.

• 11) Takahashi M. Moriguchi S. Suganuma H. Shiota A. Yoshikawa M et al.:Identification of casoxin C. an ileum-contracting peptide derived from bovine κ-casein. as an agonist for C3a receptors. Peptides 18:329-336, 1997.

• 12) Ohinata K. Inui A. Asakawa A. Wada K. Yoshikawa M et al.:Albutensin A and complement C3a decrease food intake in mice. Peptides 23:127-133, 2002.
  pubmed

• 13) Yamauchi R. Usui H. Yunden J. Takenaka Y. Yoshikawa M et al.:Characterization ofβ-lactotensin. abioactive peptide derived from bovine β-lactoglobulin. as a neurotensin agonist. Biosci Biotechnol Biochem 67:940-943, 2003.

• 14) Yamauchi R. Sonoda S. Yunden J. Yoshikawa Y:Antinociception induced by β-actotensin. a neurotensin agonist peptide derived from β-lactoglobulin. is mediated by NT2 and D1 receptors. Life Sci 73:1917-1923, 2003.

• 15) Yamauchi R. Yoshikawa M:β-Lactotensin and neurotensin rapidly reduce serum cholesterol via NT2 receptor. Peptides 24:1955-1961, 2003.

• 16) Ohinata K. Sonoda S. Inoue N. Yamauchi R. Wada K et al.:β-Lactotensin. a neurotensin agonist peptide derived from bovineβ-lactoglobulin. enhances memory consolidation in mice. Peptides 28:1470-1474, 2007

• 17) Tornetta MA. Foley JJ. Sarau HM. Ames RS:The mouse anaphylatoxin C3a receptor:molecula. r cloning. genomic organization. and functionai expression. J Immunol 158:5277-5282, 1997.

• 18) Gopalakrishnan V. Triggle CR. Sulakhe PV. McNeill JR:Characterization of a specific. high affinity[3H] arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role ofmagnesium. Endocrinology 118:990-997, 1986.

• 19) Takahashi M. Moriguchi S. Ikeno M. Kono S, Yoshikawa M et al.:Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin. a bioactive peptide derived from rice albumin. Peptides 17:5-12, 1996.
  pubmed

• 20) Tsuruki T. Takahata K. Yoshikawa M:Asoyderived immunostimulating peptide inhibits etoposide-induced alopecia in neonatal rats. J Invest Dermatol 122:848-850, 2004.
  pubmed

• 21) Tsuruki T. Yoshikawa M:Anti-alopecia effect of Gly-Leu-Phe an immunostimulating peptide derived from α-lactalbumin. Biosci Biotechnol Biochem 69:1633-1635, 2005.

• 22) 高瀬清美, 角田 出:ラクトフェリンによる化学療法剤の副作用軽減-ラクトフェリンの事前および事後投与の効果. ラクトフェリン2007. 日本医学館, 2007, p226-230.

P.120 掲載の参考文献

• 1) Levay PF Viljoen M:Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

• 2) Mattsby-Baltzer I. Roseanu A. Motas C. Elverfors J. Engberg I et al.:Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 40:257-262. 1996.

• 3) Yamauchi K. Wakabayashi H. Hashimoto S. Teraguchi S, Hayasawa H et al.:Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443:261-265, 1998.
  pubmed

• 4) Sekine K. Watanabe E. Nakamura J. Takasuka N. Kim DJ et al.:Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 88:523-526, 1997.
  pubmed

• 5) Wang Y. Raghunadharao D. Raman G Doval D. Advani S et al.:Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial. J Clin Oncol 24:7095, 2006.

• 6) Nojima Y. Suzuki Y. Iguchi K. Shiga T. Iwata A et al.:Development of Poly(ethylene glycol)Conjugated Lactoferrin for Oral Administration. Bioconjugate Chem 19:2253-2259, 2008.

• 7) Grey A. Banovic T. Zhu Q. Watson M. Callon K et al.:The low-density lipoprotein receptor-related protein lis a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268-2278, 2004.

• 8) Suzuki YA. Shin K. Lonnerdal B:Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40:15771-15779. 2001.
  pubmed

• 9) Hwang DY. Cho JS. Oh JH. Shim SB. Jee SW et al.:Differentially expressed genes in transgenic mice carrying human mutant presenilin-2(N1411):correlation of selenoprotein M with Alzheimer's disease. Neurochem Res 30:1009-1019, 2005.

• 10) Egloff AM. Vella LA. Finn OJ:Cyclin BI and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 66:6-9, 2006.

• 11) Williams GH. Swinn R. Prevost AT. De Clive-Lowe P. Halsall I et al.:Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates. Br J Cancer 91:714-719, 2004.
  pubmed

• 12) Guida T. Salvatore G. Faviana P. Giannini R. Garcia-Rostan G et al.:Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. J Clin Endocrinol Metab 90 4703-4709, 2005.
  pubmed

• 13) Yang G. Xu Y. Chen X. Hu G:IFITMI plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 26:594-603, 2007.

• 14) Andreu P. Colnot S. Godard C. Laurent-Puig P. Lamarque D et al.:Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 66:1949-1955, 2006.
  pubmed

P.126 掲載の参考文献

• 1) van der Kraan MIA, Groenink J, Nazmi K, Veerman ECI, Bolscher JGM et al.:Lactoferrampin:a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25:2093-2097, 2005

• 2) Haney EF, Lau F, Vogel HJ:Solution structure and model membrane interactions of lactoferrampin, an antimicrobial peptide derived from bovine lactoferrin. Biochim Biophys Acta 1768:2355-2364, 2007
  pubmed

• 3) van der Kraan MIA, Groenink J, Nazmi K, Teeken A, Veerlnan ECI:Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exhibits its candidacidal activity by a cluster of positively charged residues at the C-terminus in combination with a helix-facilitatng N-terminal part. Biol Chem 386:137-142, 2005

• 4) van der Kraan MIA. van der Made C, Nazmi K, van't Hof W, Veerman ECI et al.:Effect of amino acid substitutions on the candidacidal activity of LFampin 265-284. Peptides 26:2093-2097, 2005
  pubmed

• 5) Saito H, Ando I:High-resolution solid-state NMR studies on synthetic and biological macromolecules. Annu Rep NMR Spectrosc 21:209-290, 1989

• 6) Toraya S, Nishimura K, Naito A:Dynamic structure of vesicle-bound nielittin in a variety of lipid chain lengths by solid-state NMR. Biophys J 87:3323-3335, 2004

P.130 掲載の参考文献

• 1) Wagner VE, Iglewski BH:P. aeruginosa Biofilms in CF Infection. Clin Rev Allergy lmmunol 35:124-134, 2008.
  pubmed

• 2) Costerton JW, Stewart PS, Greenberg EP:Bacterial biofilms:acommon cause of persistent infections. Science 284:1318-1322, 1999.

• 3) Orsi N:The antimicrobial activity of lactoferrin:Current status and perspectives. Biometals 17:189-196, 2004.
  pubmed

• 4) Singh PK, Parsek MR. Greenberg EP, Welsh MJ:A component of innate immunity prevents bacterial biofilm development. Nature 417:552-555, 2002.
  pubmed

• 5) Merritt JH, Kadouri DE, O'Toole GA:Growing and analyzing static biofilms. Curr Protoc Microbiol Chapter 1:Unit IB. 1, 2005.

• 6) Singh PK:Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals l7:267-270, 2004.

• 7) Banin EB, Vasil ML, Greenberg EP:Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci 102:11076-11081, 2005.

• 8) Rogan MP, Taggart CC, Greene CM, Murphy PG, O'Neill SJ:Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 190:1245-1253, 2004.
  pubmed

• 9) Ammons MC, Ward LS, Fisher ST, Wolcott RD, James GA:In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aerorginosa treated with lactoferrin and xylitol. Int J Antimicrob Agents 33:230-236, 2009.
  pubmed

P.135 掲載の参考文献

• 1) Allen JC, Wrieden WL:Influence of milk proteins on lipid oxidation in aqueous emulsion I. Casein, whey protein and α-lactalbumin. Journal of Dairy Research 49:239-248, 1982a.

• 2) Allen JC, Wrieden WL:Infiuence of milk proteins on lipid oxidation in aqueous emulsion II. Lactoperoxidase, lactoferrin, superoxide dismutase and xanthine oxidase. Journal of Dairy Research 49:249-263, 1982b.

• 3) Baker HM, Anderson BF, Baker EN Dealing with iron:Common structural principles in proteins that transport iron and heme. Proceedings National Academy of Sciences of the United States of America 100:3579-3583, 2003.

• 4) Cervato G, Cazzola R, Cestaro B:Studies on the antioxidant activity of milk caseins. International Journal of Food Sciences and nutrition 50:291-294, 1999.
  pubmed

• 5) Chance B:Catalases and peroxidases, part II. Methods of Biochemical Analysis 1:408-424, 1954.

• 6) Colbert LB, Decker EA:Antioxidant activity of an ultrafiltration permeate from acid and whey. Journal Food Science 56:1249-1250, 1991.

• 7) Donnelly JL, Decker EA, McClements DJ:Ability of emulsifiers to influence iron-catalyzed oxidation of emulsified menhaden oil. Journal Food Science 63:997-1000, 1998.

• 8) Gutteridge JMC, Paterson SK, Segal AW and HalliwellB:Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochemical Journal 199:259-261, 1981.

• 9) Halliwell B:Role of free radicals in the neurodegenerative diseases:Therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716, 2001.
  pubmed

• 10) Hernandez-Ledesma B, Davalos A, Bartolome B and Amigo L:Preparation of antioxidant enzymatic hydrolysates from α-lactalbumin and β-lactoglobulin. Identification of active peptides by HPLC-MS/MS. Journal of Agricultural and Food Chemistry 53:588-593, 2005.

• 11) Huang S-W, Satue-Gracia M T, Frankel E N and German JB:Effect of lactoferrin on oxidative stability of corn-oil emulsions and liposomes. Journal of Agricultural and Food Chemistry 47:1356-1361, 1999.
  pubmed

• 12) Kitts DD and Weiler K:Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Current Pharmaceutical Design 9:1309-1323, 2003.
  pubmed

• 13) Michelson AM:Clinical use of superoxide dismumutase and possible pharmacological approaches. Academic Press, New York, 1982, p277-302.

• 14) Nagano T, Hiraro T and Hirobe M:Superoxide dismutase mimics based on iron in vivo. Journal of Biological Chemistry 264:9243-9249, 1989.

• 15) Ostdal H, Daneshvar B, Skibsted LH:Reduction of ferrylmyoglobin by β-lactoglobulin. Free Radical Research 24:429-438, 1996.

• 16) Taylor MJ, Richardson T:Antioxidant activity of skimmilk:effect of heat and resultant sulfhydryl groups. Journal of Dairy Science 63:1783-1795, 1980.

• 17) Wong PYY and Kitts DD:Chemistry of buttermilk solid antioxidant activity. Journal of Dairy Science 86 :1541-1547, 2003.
  pubmed

• 18) Zhao ZS, Khan S, O'Brien PJ:Catecholic iron complexes as cytoprotective superoxide scavengers against hypoxia:reoxygenation injury in isolated hepatocytes. Biochemical Pharmacology 56:825-830, 1998.

P.141 掲載の参考文献

• 1) Bortner CA, Miller RD, Arnold RR:Bactericidal effect of lactoferrin on Legionella pneumoPhila. Infect Immun 51:373-377, 1986.
  pubmed

• 2) Matsue M, Tomita S, Nyui S, Matsuyama J, Kiyosawa I:Suppressive effects of lactoferrin on bleomycin-dependent DNA damage by the iron ion and ascorbate. Biosci Biotechnol Biochem 58:67-71, 1994.

• 3) 冨田信一, 魚谷孝之, 松山 惇:ラクトフェリンのBifidobacterium菌体への結合性と増殖性との関係. ラクトフェリン2007. 日本医学館, 2007, p141-147.

P.146 掲載の参考文献

• 1) Kitagawa H, Yoshizawa Y, Yokoyama T, Takeuchi T, Talukder MJR et al.:Persorption of bovine lactoferrin from the intestinal lumen into the systemic circulation via the portal vein and the mesenteric lymphatics in growing pigs. J Vet Med Sci 65:567-572, 2003.

• 2) Takeuchi T, Kitagawa H. Harada E:Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Exp Physiol 89:263-270, 2004.
  pubmed

• 3) Harada E, Sugiyama A, Takeuchi T, Sitizyo K, Syuto B et al.:Characteristic transfer of colostral components into cerebrospinal fluid via serum in neonatal pigs. Biol Neonate 76:33-43, 1999.
  pubmed

• 4) Harada E, Itoh Y, Sitizyo K, Takeuchi T. Araki Y et al.:Characteristic transport of lactoferrin from the intestinal lumen into the bile via the blood in piglets. Comp Biochem Physiol 124A:321-327, 1999.

• 5) Harada E, Araki Y, Furumura E, Takeuchi T, Sitizyo Ket al.:Characteristic transfer of colostrum derived biologically active substances into cerebrospinal fluid via biood in natural suckling neonatal pigs. J Vet Med A49:358-364. 2002.

• 6) Kamemori N, Takeuchi T, Sugiyama A, Miyabayashi M, Kitagawa H, ct al.:Trans-endothelial and transepithelial transfer of lactoferrin into the brairi through BBB and BCSFB in adult rats. J Vet Med Sci 70:313-315. 2008.

• 7) Hayashida K. Takeuchi T. Shimizu H, Ando K, Harada E:Novel central function of milk-derived lactoferrin on anti-nociception mediated by the μ-opioid receptor. Brain Res 965:239-245, 2003.

• 8) Takeuchi T, Hayashida K, Inagaki H, Kuwahara M, Tsubone H et al.:Opioid lnediated suppressive effect of milk-derived lactoferrin on distress induced by maternal seperation in the rat pups. Res 979 1216-224, 2003.

• 9) Kamemori N, Takeuchi T, Hayashida K, Harada E:Suppressive effects of milk-derived lactoferrin on the psychological stress in adult rats. Brain Res 1029:34-40, 2004.
  pubmed

• 10) Tsuchiya T. Takeuchi T. Hayashida K, Harada E:Milk-derived lactoferrin may block tolerance to morphine analgesia. Brain Res 1068:102-108, 2006.
  pubmed

• 11) Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E:Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spillal cord. Am J physiol 285:R306-R312, 2003.

• 12) Hayashida K. Takeuchi T, Harada E:Lactoferrin enhances peripheral opioid-mediated antinociception via nitric oxide in rats. Eur J Pharm 484:175-181. 2004.

• 13) Nojima Y, Suzuki Y, lguchi K, Shiga T, Iwata A et al.:Development of poly(ethylene glycol)conjugated lactoferrin for oral administration. Bioconjugate Chem 19:2253-2259, 2008.

• 14) Wang YS, Youngster S, Grace M, Bausch J, Bordens R et al. l Structural and biological characterization of peglylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Delivery Rev 54:547-570, 2002.

• 15) Kodera Y, Tanaka H, Matsushima A, Inada Y:Chemical modification of L-asparaginase with a colnb-shaped copolymer of polyethylene glycol derivative and maleic anhydride. Biochem Biophys Res Commun 184:144-148, 1992.
  pubmed

• 16) Cindric M, Cepo T, Galic N, Bukvic-Krajacic M, Tomczyk N et al.:Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharm Biomed Anal 44:388-395, 2007.

P.152 掲載の参考文献

• 1) Ingber DE, Mow VC, Butler D, Niklason L, Huard J et al.:Tissue engineering and developmental biology:going biomimetic. Tissue Eng 12:3265-3283, 2006.
  pubmed

• 2) Cen L, Liu W, Cui L, Zhang W, Cao Y:Collagen tissue engineering:development of novel biomaterials and applications. Pediatr Res 63:492-496, 2008.

• 3) 名井 陽, 西川昌孝, 藤本哲穂, 木澤卓嗣, 山崎直美・ 他:骨欠損の治療-人工骨と間葉系幹細胞を利用した再生医療-生体医工学 44:530-536, 2006.

• 4) 田畑泰彦:ドラッグデリバリー-システム. 再生医療のためのバイオマテリアル. (田畑泰彦・編), コロナ社, 2006, p160-178.

• 5) 田畑泰彦:ドラッグデリバリー-システムとティッシュエンジニアリング. ティッシュエンジニアリング 2005. (川畑泰彦・岡野光夫・編), 日本医学館, 2005, p92-99.

• 6) Behring J, Junker R, Walboomers XF, Chessnut B. Jansen JA:Toward guided tissue and bone regeneration:morphology, attachment, proliferation, and migration of cells cultured on collagen barrier membranes. A systematic review. Odontology 96:1-11, 2008.
  pubmed

• 7) 金 完燮, 島崎敬一:ラクトフェリンと微生物の攻防:その多様性. ラクトフェリン2007. 日本医学館, 2007, p9-17.

• 8) Legrand D, Elass E, Pierce. IX. Mazurier J:Lactoferrin and host defence:an overview of its immuno-modulating and anti-inflammatory properties. Biometals 17:225-229, 2004.

• 9) Shimamura M, Yamamoto Y. Ashino H, Oikawa T, Hazato T et al.:Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer 111:111-116, 2004.
  pubmed

• 10) Takayama Y, Takahashi H. Mizumachi K, Takezawa T:Low density lipoprotein receptor-related protein (LRP)is required for lactoferrin-enhanced collagen gel contractile activity of human fibroblasts. J Biol Chem 278:22112-22118, 2003.
  pubmed

• 11) Grey A, Banovic T, Zhu Q, Watson M, Callon K et al.:The low-density lipoprotein receptor-related protein lis a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268-2278, 2004.

• 12) Takayama Y, Mizumachi K:Effect of bovine lactoferrin on the extracellular matrix calcification by human osteoblast-like cells. Biosci Biotechnol Biochem 72:226-230, 2008.
  pubmed

• 13) Cornish J, Palmano K, Callon KE, Watson M, Lin JM et al.:Lactoferrin and bone; structure-activity relationships. Biochem Cell Biol 84:297-302, 2006.
  pubmed

• 14) Takayama Y, Mizumachi K:Effect of lactoferrin-embedded collagen membrane on osteogenic differentiation of human osteoblast-like cells. J Biosci Bioeng 107:191-195, 2009.

• 15) 平野義明:機能性足場. 再生医療のためのバイオマテリアル. (田畑泰彦・編), コロナ社, 2006, p122-144.

• 16) 山内恒治:乳中の生体防御物質「ラクトフェリン」の応用. FFIジャーナル 211:771-776, 2006.

P.157 掲載の参考文献

• 1) Prusiner SB:Novel proteinaceous infectious particles cause scrapie. Science 216:136-144, 1982.
  pubmed

• 2) Prusiner SB:Molecular biology of prion diseases. Science 252:1515-1522, 1991.
  pubmed

• 3) Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S et al.:Treatment of transmissible spongi-form encephalopathy by intraventricular drug infusion in animal models. J Virol 78:4999-5006, 2004.

• 4) Kawamata T, Tooyama I. Yamada T, Walker DG, McGeer PL:Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J pathol 142:1574-1585, 1993.

• 5) Lcveugle B. Spik G, Perl DP, Bouras C, Fillit HM et al.:The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodege-nerative disorders:acomparative immunohisto-chemical analysis. Brain Res 650:20-31, 1994.

• 6) Kim CL, Karino A, lshiguro N, Shinagawa M, Sato M et al.:Cell-surface retention of PrPc by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 85:3473-3482, 2004.
  pubmed

• 7) Feraudet C, Morel N, Simon S, Volland H, Frobert Y et al.:Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 280:11247-11258, 2005.

• 8) Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly Ket al.:Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J 20:377-386, 2001.

• 9) Iwamaru Y, Shimizu Y. Imamura M Murayama Y, Endo R et al.:Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation. J Neurochem 107:636-646. 2008.
  pubmed

P.160 掲載の参考文献

• 1) Pras M, Schubert M, Zucker-Frankin D et al.:The characterization of soluble amyloid prepared in water. J Clin Invest 47:924-933, 1968.

• 2) Munier FL, Korvatska E, Djemai A et al.:Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nature Genetics 15:247-251, 1997.
  pubmed

• 3) Tsujikawa M. Kurahashi H, Tanaka T et al.:Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nature Genetics 21:420-423, 1999.
  pubmed

• 4) Tsutsumi Y, Serizawa A, Hori S:Localized amyloidosis of the seminal vesicle:Identification of lactoferrin immunoreactivity in the amyloid material. Pathology International 46:491-497. 1996.
  pubmed

• 5) Klintworth GK. Valnickova Z. Keilar RA et al.:Familial subepithelial corneal amyloidosis-A lactoferrin-related amyioidosis. Invest Ophthalmol Vis Sci 38:2756-2763. 1997.

• 6) Ando Y, Nakamura M, Kai H et al.:Anovel localized amyloidosis associated with lactoferrin in the cornea. Lab Invest 82:757-765, 2002.

• 7) Araki-Sasaki K Ando Y, Nakamura M et al.:Lactoferrin Glu56lAsp facilitates secondary amyloidosis in the cornea. Br J Ophthalmol 89:684-688, 2005.
  pubmed

• 8) Araki-Sasaki K, Obata H, Yamada M et al.:The clinical characteristics of secondary corneal amyloidosis. Rinsho Ganka 61:1641-1644, 2007.

• 9) Nilsson MR, Dobson CM:In vitro characterization of lactoferrin aggregation and amyloid formation. Biochemistry 42:375-382, 2003.
  pubmed

• 10) Matsuda E, Fujita K, Iigo M et al.:The N-terminal Gly, Arg, Arg, Arg and Arg sequence of human lactoferrin is essential for it's localization to the nucleus. Milk Science 53:343-347, 2004.

• 11) Santagati MG, La Terra Male S, Amico C et al.:Lactoferrin expression by bovine ocular surface epithelia:aprimary cell culture model to study lactoferrin gene promoter activity. Ophthalmic Res 37:270-278, 2005.

• 12) Kaoru Araki-Sasaki, Ohashi Y, Sasabe T et al.:An SV40-immoralized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci 36:614-621, 1995.

• 13) Takaoka M, Nakamura T, Ban Y et al.:Phenotypic investigation of cell junction-related proteins in gelationous drop-like corneal dystrophy. Invest Ophthalmol Vis Sci 48:1095-1101, 2007.

P.167 掲載の参考文献

• Amin HS, Liss GM, Bernstein DI:Evaluation of near-fetal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 117:169-675. 2006.

• Andersson B, Dahman J, Frejd, T, Leffler H, Mugnusson G et aL:Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J Exp Med 158:559-570, 1983.

• Arbes SJ, Gergen PJ, Elliott L, Zeldin DC:Prevalences of positive skin test responses to 10 common allergens in the US population:Results from the Third National Health and Nutrition Examination Survey. J AIIergy Clin Immunol 116:377-383, 2005.
  pubmed

• Bhombal S, Bothwell MR, Bauer SM:Prevalence of elevated total IgE and food allergies in a consecutive series of ENT pediatric patients. Otolaryngology-Head and Neck Surgery 134:578-580, 2006.

• Brock J:Lactoferrin:amultifunctional immunoregulatory protein? Immunol Today 16:417-419, 1995.

• Broide DH:Molecular and cellular mechanism of allergic disease. J AIIergy Clin Immunol 108:S65-S71. 2001.

• Romagnani S:The role of lmphocytes in allergic disease. J AIIergy Clin Immunol 105:399-408, 2000.

• Crameri R, Rhyner C:Novel vaccines and adjuvants for allergen-specific immunotherapy. Current Opinion in Immunology 18:761-768, 2006.
  pubmed

• Fiat AM, Jolles P:Caseins of various origins and biologically active casein peptides and oligosaccharides:structural and physiological aspects. Mol Cell Biochem 87:5-30, 1989.
  pubmed

• Hakansson A, Zhivotovski B, Orrenius S, Sabharwal H, Svanborg C:Apoptosis induced by a human milk protein. Proc Natl Acad Sci USA 92:8064-8068, 1995.

• Hauer J, Voetsh W, Anderer FA:Identification of a mannose-acetate-specific 87-kDa receptor responsible for human NK and LAK activity. Immunol Lett 42:7-12, 1994

• He J, Furmanski P:Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721-724, 1995.
  pubmed

• Lima MF, Kierzenbaum F:Lactoferrin effects of phagocytic cell function. II. The presence of iron is required for the lactoferrin molecule to stimulate intracellular killing by macrophages but not to enhance the uptake of particles and microorganisms. J Immunol 139:1647-1651, 1987.

• Mosmann TR, Cherwinski H, Bond MW, Giedli MA, Coffman RL:Two types of murine T cell clone, I:definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357, 1986.

• Oppenheimer JJ, Nelson HS, Bock SA, Christiansen F, Leung DYM:Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90:256-262, 1992

• Ragusa FV, Passalacqua G, Gambardella R, Campanari S, Barbieri MM et al.:Nonfetal systemic reactions to subcutaneous immunotherapy:a 10-year experience. J Investig Allergol Clin Immunol 7:151-154, 1997.

• SnapPer CM, Peschel C, Paul WEJ:INF-γ stimulates IgGa secretion by murine B cells stimulated with bacterial LPS. J Immunol 140:2121-2127, 1988.

• Yoo YC, Watanabe R, Koike Y. Mitobe M, Shimazaki K et al.:Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide:involvement of reactive oxygen species. Biochem Biophys Res Commun 237:624-628, 1997.
  pubmed

• Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z:Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 70:697-704, 1989.
  pubmed

P.173 掲載の参考文献

• 1) Strobel S, Mowat AM:Immune responses to dietary antigens:oral tolerance. Immunol Today 19:173-181, 1998.

• 2) Lonnerdal B, Iyer S:Lactoferrin:molecular structure and biological function. Annu Rev Nutr 15:93-110, 1995.
  pubmed

• 3) Legrand D, Elass E, Carpentier M, Mazurier J l Lactoferrin:amodulator of immune and inflammatory responses. Cell Mol Life Sci 62:2549-2559, 2005.

• 4) Ward PP, Paz E, Conneely OM:Multifunctional roles of lactoferrin:acritical overview. Cell Mol Life Sci 62:2540-2548, 2005.

• 5) Aschaffenburg R, Drewry J:Improved method for the preparation of crystalline B-lactoglobulin and α-lactalbumin from cow's milk. Biochem J 65:273-277, 1957.

• 6) Bogard WC Jr, Kato I, Laskowski M Jr:A Ser162/Gly162 polymorphism in Japanese quail ovomucoid. J Biol Chem 255:6569-6574, 1980.
  pubmed

• 7) Fischer R, Debbabi H, Dubarry M, Boyaka P, Tome D:Regulation of physiological and pathological Thl and Th2 responses by lactoferrin. Biochem Cell Biol 84:303-311, 2006.

• 8) Sekine K, Ushida Y, Kuhara T, Iigo M, Baba-Toriyama H et al.:Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Lett 121:211-216, 1997.
  pubmed

• 9) Debbabi H, Dubarry M, Rautureau M, Tome D:Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res 65:283-293, 1998.
  pubmed

• 10) Hwang SA, Wilk KM, Bangale YA, Kruzel ML, Actor JK:Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol 196:171-180, 2007.
  pubmed

• 11) Cumberbatch M, Dearman RJ, Uribe-Luna S, Headon DR, Ward PP et al.:Regulation of epidermal Langer-hans cell migration by lactoferrin. Immunology 100:21-28, 2000.

• 12) Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tome D:The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr 134:403-409, 2004.
  pubmed

• 13) Troost FJ, Steijns J, Saris WH, Brummer RJ:Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr 131:2101-2104, 2001.
  pubmed

• 14) Balmer SE, Scott PH, Wharton BA:Diet and faecal flora in the newborn:lactoferrin. Arch Dis Child 64:1685-1690, 1989.
  pubmed

• 15) Hu WL, MazurierJ, Montreuil J, Spik G:Isolation and partial characterization of a lactotransferrin receptor from mouse intestinal brush border. Biochemistry 29:535-541, 1990.
  pubmed

• 16) Suzuki YA, Lopez V, Lonnerdal B:Mammalian lactoferrin receptors:structure and function. Cell Mol Life Sci 62:2560-2575, 2005.
  pubmed

• 17) Kato I, Schrode J, Kohr WJ, Laskowski M Jr:Chicken ovomucoid:determination of its amino acid sequence, determination of the trypsin reactive site, and preparation of all three of its domains. Biochemistry 26:193-201, 1987.
  pubmed

P.177 掲載の参考文献

• 1) Levay PF, Viljoen M:Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

• 2) Nozaki A, Ikeda M, Naganuma A, Nakamura T, Inudoh M et al.:ldentification of a lactoferrin derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278:10162-10173, 2003.

• 3) Hutchens TW, Henly JF, Yip T-T:Structurally intact (78-kDa)forms of maternal lactoferrin purified from urine of preterm infants fed human milk:identification of trypsin-like proteolytic cleavage event in vivo that does not result in fragment dissociation. Proc Natl Acad Sci USA 88:2994-2998, 1991.

• 4) Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H et al.:Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C:apilot study. JPn J Cancer Res 90:367-371, 1999.

• 5) Takakura N, Wakabayashi H, Yamauchi K, Takase M:lnfluences of orally administered lactoferrin on IFN-gamma and IL-10 production by intestinal intraepitherial lymphocytes and mesenteric lymph node-cells. Biochem Cell Biol 84(3)1363-368, 2006.

• 6) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28:893-898, 1980.
  pubmed

• 7) van der Strate BW, Beljaars L Molema G, Harmsen MC, Meijer DK:Antiviral activities of lactoferrin. Antiviral Res 52:225-239, 2001.
  pubmed

• 8) Brock J:Lactoferrin:amultfunctional immunore-gulatory protein? Immunol Today 16(9):417-419, 1995.

• 9) Cohen MS. Mao J, Rasmussen GT, Serody JS, Britigan BE:Interaction of lactoferrin and lipopolysaccharide (LPS):effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J Infect Dis 166:1375-1378, 1992.
  pubmed

• 10) Hagiwara T, Ozawa K, Fukuwatari Y, Hayasawa H, Hirohata Y et al.:Effects of lactoferrin on iron absorption in immature mice. Nutrition Research 17:895-906, 1997.

• 11) Ishii K, Sumino Y., Higami K:Long-term Follow-up of Chronic Hepatitis C Patients After Oral Lactoferrin Administration. Food function 3(1):1-6, 2007.

• 12) Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H:Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245:549-553, 1998.
  pubmed

• 13) Okada S, Tanaka K, Sato T, Ueno H, Saito S:Dose-response trial of lactoferrin in patients with chronic hepatitis C. JPn J Cancer Res 93(9):1063-1069, 2002.
  pubmed

• 14) Iwasa M, Kaito M, Ikoma J, Takeo M, Imoto I:Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype lb. Am J Gastroenterol 97(3):766-767, 2002.

• 15) Hirashima N, Orito E, Ohba K, Kondo H, Sakamoto T:Arandomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype lband high viral load. Hepatol Res 29(1):9-12, 2004.

• 16) Ishibashi Y, Takeda K, Tsukidate N, Miyazaki H, Ohira K:Randomized placebocontrolled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 32 (4):218-223, 2005.
  pubmed

• 17) Ishii K, Takamura N, Shinohara M, Wakui N, Shin H et al.:Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 25(3):226-233, 2003.
  pubmed

• 18) Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K:Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192-199, 2000.
  pubmed

• 19) Higami K, Ishii K, Sumino Y, Matsumaru K, Takamura N:Sustained Virological Response Rate and Host Background in Chronic Hepatitis C Patients Receiving Various Interferon Therapies. Inflammation and Regeneration 27(3):187-193, 2007.

• 20) Higami K, Ishii K, Sumino Y:Interleukin-18/interleukin 10 ratio is an independent predictor of SVR patients treated with IFN-based therapy. Inflammation and Regeneration 28(3):137-143, 2009.

P.182 掲載の参考文献

• 1) 安藤邦雄:アンチエイジングとラクトフェリン. 第1回歯科ラクトフェリンシンポジウム抄録集, 2008, p3-15.

• 2) 坪田昭人:酸化ストレス状態におけるラクトフェリンの効果と作用機序. 第1回歯科ラクトフェリンシンポジウム抄録集, 2008, p27-33.

• 3) 坂本順一:水の百科事典 (高橋 裕・他編), 丸善, 1998, p295-296.

• 4) 宮西ナオ子:唾液は何でも知っている!. 三五館, 2006.

• 5) 田中喜秀:唾液ストレス関連成分の迅速分析法. 臨床検査 52(4):441-449, 2008.

P.190 掲載の参考文献

• 1) 島崎敬一:ラクトフェリンの多機能性をどう説明するか. ミルクサイエンス 53(4):365-368, 2004.

• 2) Kushida T, Asanuma T, Okuda Y, Shidahara Y, Takagi T:Collection of Disease Networks by Hybrid Curation Method and the Application for Pathway Analysis. International Conference on Complex, Intelligent and Software Intensive Systems 2009, p800-806.

• 3) Raychaudhuri S:Computational Text Analysis for Functional Genomics and Bioinformatic. Oxford University Press. England, 2006, p1-312.

• 4) Shannon P, Markiel A, Ozier O, Baliga NS. Wang JT ct al.:Cytoscape:asoftware environment for integrat-ed models of biomolecular interaction networks. Genome Research 13(11):2498-2504, 2003.

• 5) Norrby K:Human apo-lactoiferrin enhances angio-genesis mediated by vascular endothelial growth factor A in vivo. J Vasc Res 41(4):293-304, 2004.

• 6) Kim CW, Son KN, Choi SY. Kim J:Human iactoferrin upregulates expression of KDR/Flk-l and stimulates VEGF-A-mediated endothelial cell proliferation and migration. FEBS Lett 580(18):4332-4336, 2006.

• 7) Stokes K, Alston-Mills B, Teng C:Estrogen response element and the promoter context of the human and mouse lactoferrin genes influence estrogen receptor alpha-mediated transactivation activity in mammary gland cells. J Mol Endocrinol 33(2):315-334, 2004.

• 8) Zaitseva M, Yue DS. Katzenellenbogen JA, Rogers PA, Gargett CE:Estrogen receptor-alpha agonists promote angiogenesis in human myometrial microvas-cular endothelial cells. J Soc Gynecol Investig 11 (8):529-535, 2004.

• 9) Crabtree JE, Lindley IJ:Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease. Eur J Gastroenterol Hepatol 6 Suppl 1:S33-38, 1994.
  pubmed

• 10) Lakshminarayanan V, Drab-Weiss EA, Roebuck KA:H202 and tumor necrosis factor-alpha induce differential binding of the redox-responsive transcription factors AP-l and NF-kappaB to the interleukin-8 promoter in endothelial and epithelial cells. J Biol Chem 273(49):32670-32678, 1998.

• 11) Crouch SP, Slater KJ, Fletcher J:Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 80(1):235-240, 1992.
  pubmed

• 12) Son KN, Park J, Chug CK, Chung DK, Yu DY et al.:Human lactoferrin activates transcription of IL-lbeta gene in mammalian cells. Biochem Biophys Res Commun 290(1):236-241. 2002.

• 13) Mathy-Hartert M, Martin G, Devel P. Deby-Dupont G, Pujol Jp et al.:Reactive oxygen species downregu-late the expression of pro-inflammatory genes by human chondrocytes. Inflamm Res 52(3):111-118, 2003.

P.195 掲載の参考文献

• 1) Levay PF and Viljoen M:Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

• 2) Mattsby-Baltzer I, Roseanu A, Motas C, Elerforts J, Engberg I et al.:Lactoferrin or a fragment thereof inhibits the endotoxin-inducedinterleukin-6 response in human monocytic cells. Pediatr Res 40:257-262, 1996.
  pubmed

• 3) Chierici R, Sawatzki G, Tamisari L, Volpato S, Vigi V:Supplementation of an adapted formula with bovine lactoferrin. 2. Effects on serum iron, ferritin and zinc levels. Acta Paediatr 81:475-479, 1992.
  pubmed

• 4) Ikeda M, sugiyama K Tanaka T, Tanaka K, Sekihara Het al.:Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochern Biophys Res Commum 245:549-553, 1998.

• 5) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28:893-898. 1980.
  pubmed

• 6) Baldwin DA, Jenny ER. Aisen P:The effect of human serum transferrin and milk lactoferrin on hydroxyl radical formation from superoxide and hydrogen peroxide. J Biol Chem 259:13391-13394, 1984.
  pubmed

• 7) Kodera Y, Tanaka H, Matsushima A, Inada Y:Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol deriv ative and maleic anhydride. Biochem Biophy Res Commun 184:144-148. 1992.

• 8) Wang YS, Youngster S, Grace M, Bausch J, Bordens R et al.:Structural and biological characterization of pagylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Delivery Rev 54:547-570, 2002.

• 9) Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ et al.:Rational design of a potent, long-lasting form of interferon:a40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12:19-202, 2001.

• 10) Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A et al.:Development of Poly(ethylene glycol)Conjugated Lactoferrin for Oral Administration. Bioconjugate Chem 19:2253-2259, 2008.

• 11) Kurfurst MM:Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacry-lamide gel electrophoresis. Anal Biochem 200:244-248, 1992.

• 12) Shimazaki K, Hosokawa T:Atentative method for rapid preparation of iron-saturated lactoferrin by affinity chromatography. Anim Sci Technol 62:354-356, 1991.

P.200 掲載の参考文献

• 1) Levay PF, Viljoen M:Lactoferrin:a general review. Haematologica 80:252-267, 1995.
  pubmed

• 2) Mattsby-Baltzer I, Roseanu A, Motas C, Elerforts J, Engberg I et al.:Lactoferrin or a fragment thereof inhibits the endotoxin-inducedinterleukin-6 response in human monocytic cells. Pediatr Res 40:257-262, 1996.
  pubmed

• 3) Chierici R, Sawatzki G, Tamisari L, Volpato S. Vigi V:Supplementation of an adapted formula with bovine lactoferrin. 2. Effects on serum iron, ferritin and zinc levels. Acta Paediatr 81:475-479, 1992.
  pubmed

• 4) Arnold RR, Brewer M, Gauthier JJ:Bactericidal activity of human lactoferrin:sensitivity of a variety of microorganisms. Infect Immun 28:893-898, 1980.
  pubmed

• 5) Kodera Y, Tanaka H, Matsushima A, Inada Y:Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol deriv-ative and maleic anhydride. Biochem Biophy Res Commun 184:144-148, 1992.

• 6) Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ et al.:Rational design of a potent, long-lasting form of interferon:a40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12:195-202, 2001.

• 7) Nojima Y, Suzuki Y, Kazuma I, Tuneo S, Aya I et al.:Development of poly(ethylene glycol)conjugated lactoferrin for oral administration. Bioconjugate Chem 19:2253-2259, 2008.

• 8) Veronese FM, Pasut G:PEGylation, successful ap-proach to drug delivery:Drug Discov Today 101 1451-1458, 2005.

• 9) Kurfurst MM:Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacry-lamide gel electrophoresis. Anal Biochem 200:244-248, 1992.

• 10) Shimazaki K, Hosokawa T:Atentative method for rapid preparation of iron-saturated lactoferrin by affinity chromatography. Anim Sci Technol 62:354-356. 1991.